First of a new breed of anticancer antibodies approved in Japan


The first in a new class of immune-oncology drugs has been approved for use in Japan. Ono pharmaceuticals’ Opdivo (nivolumab) has been approved for treating melanomas where surgery is impossible.

Nivolumab is part of a new wave of cancer therapies that encourage our immune systems to fight cancers or enhance their performance. It targets programmed cell death (PD1) receptors that are expressed on tumour cell surfaces to ward off detection by the immune system.

Ono developed the monoclonal antibody in conjunction with US biotech Medarex, which was acquired by Bristol-Myers Squib (BMS) in 2009. BMS is developing the drug outside of Japan, Korea and Taiwan.


Related Content

First biosimilar antibody drugs approved in Europe

11 September 2013 Business

news image

European commission gives final approval to generic infliximab copies

Business roundup

29 September 2011 Business

news image

Industry news, October 2011

Most Read

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines

MDMA

9 October 2014 Podcast | Compounds

news image

The drug that fuelled rave culture may yet be a treatment for PTSD. Hayley Simon introduces MDMA

Most Commented

Cannabis chemists look for professional recognition

16 October 2014 News and Analysis

news image

The American Chemical Society is being petitioned to form a division to help develop standards in the field

Not all science is created equal

16 October 2014 Comments

news image

John Ioannidis explains why researchers should be curious about the differences between disciplines